Immunic is trading 6.53% up at $15.49, extending the August 6, 2026 advance as biotech shares rally on renewed merger-and-acquisition optimism.
- No fresh company-specific announcement was identified for August 7, 2026; Immunic’s official news page shows no newer release.
- Earnings timing was estimated around August 6, 2026.
- The broader move followed Argenx’s tender offer for Forte Biosciences, with Immunic participating in the risk-on biotech rally.